Results from the Randomized Phase 3 Transform Study - report from ASH2021

from Medical Digest & Congress Report · host Medical Congress News

Professor Manali Kamdar speaks about Lisocabtagene Maraleucel, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma. Video: https://congressreport.eu/scientific-contents/interview:results-randomized-phase-3-transform-study

Episode metadata supplied by the publisher feed · Published Dec 16, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Results from the Randomized Phase 3 Transform Study - report from ASH2021

0:00 1:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 1 minute long.

When was this Medical Digest & Congress Report episode published?

This episode was published on December 16, 2021.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!